Failed Anti-Aging & Longevity Companies Ranked by AI Consensus
By Alex Zhavoronkov · May 2026 · Forever.ai
The rankings of the failures are provided by LLMs so that I do not offend anyone. I am in longevity for over 20 years stepping from GPU engineering and business into biotech. I have seen many companies launch and fall. In our industry, people do not like to talk about failures. Especially when it comes to products or individuals.
I remember presenting at a longevity event and mentioning several notable failures — one person in the audience actually complained that what I mentioned was not a failure. I was talking about a product that failed in a Phase 3 trial, designed in a way where no proper aging biomarkers were collected, making it impossible to tell if anything worked. The company had to give up on that project and merge with another one.
So in this article, 100% of the failures are derived from the LLMs — don't blame me.
It is important to know about and study the history of longevity biotech because very often the new is just the iteration on the forgotten past. LLMs are good at helping review the history.
Each of 4 frontier LLMs was independently asked to rank the top 50 failed longevity/anti-aging companies. Results were merged, deduplicated, and scored by cross-model consensus.
Each model was queried independently with the same prompt. No model saw another's output. Results were merged programmatically.
Companies are ranked by: (1) consensus score, then (2) average rank position across models that listed them.
Click any card to expand details. Sorted by AI consensus score and significance.
Promise: Resveratrol-based sirtuin activators to mimic calorie restriction and extend lifespan.
Failure: GSK acquired Sirtris for $720M in 2008. SRT501 caused kidney failure in diabetic patients and was terminated. SRT2104 failed Phase 2. GSK shut down the entire unit in 2013 with $0 return on the sirtuin longevity hypothesis. The poster child for hype-to-bust in longevity biotech.
Models: ✓ GPT-5.5 (#3) · ✓ Opus (#3) · ✓ DeepSeek (#2) · ✓ Kimi (#1)
Promise: Telomerase activation and embryonic stem cells to reverse cellular aging. Spent $800M+ over 20 years.
Failure: The telomerase anti-aging vision never became a longevity therapy. Embryonic stem-cell program was abandoned. Company pivoted entirely to cancer hematology (imetelstat). The original "reverse aging" mission was a complete strategic failure despite two decades of effort.
Models: ✓ GPT-5.5 (#4) · ✓ Opus (#8) · ✓ DeepSeek (#1) · ✓ Kimi (#5)
Promise: Senolytic drugs to clear senescent "zombie cells" and treat diseases of aging.
Failure: Lead senolytic UBX0101 failed Phase 2 for knee osteoarthritis in 2020 — stock dropped 70% in one day. Later UBX1325 failed Phase 2 for diabetic macular edema (2023). Stock collapsed 95%+ from IPO. The company pivoted to ophthalmology, effectively abandoning its systemic longevity/senolytic mission.
Models: ✓ GPT-5.5 (#5) · ✓ Opus (#6) · ✓ DeepSeek (#5) · ✓ Kimi (#7)
Promise: Longevity-gene drugs, sirtuin activators, and ghrelin/calorie-restriction biology. Connected to early Guarente/Sinclair research at MIT.
Failure: Burned through $100M+ with zero clinical assets reaching approval. Failed to produce an approved anti-aging drug, sold off assets, and effectively disappeared by 2009-2010. Never tested a longevity drug in humans.
Models: ✓ GPT-5.5 (#12) · ✓ Opus (#2) · ✓ DeepSeek (#3) · ✓ Kimi (#9)
Promise: mTOR inhibition (RTB101) to reverse immunosenescence and prevent respiratory illness in older adults.
Failure: Phase 3 PROTECTOR-1 trial failed in 2019 to reduce respiratory infections in the elderly. Stock dropped 90%. Company liquidated assets and merged into Adicet Bio, completely abandoning the aging program. A textbook case of a single-asset aging company evaporating after one trial failure.
Models: ✓ GPT-5.5 (#6) · ✓ Opus (#7) · ✓ DeepSeek (#21) · ✓ Kimi (#4)
Promise: Young plasma proteins and plasma fractions to reverse brain aging, based on parabiosis research.
Failure: GRF6019 failed Alzheimer's trials. Grifols acquired the company for $146M but then terminated the partnership (2022) after Phase 2 failures. Plasma fractions failed to slow cognitive decline. The "young blood" longevity promise disappeared into conventional plasma programs. Company dissolved.
Models: ✓ GPT-5.5 (#7) · ✓ Opus (#12) · ✓ DeepSeek (#25) · ✓ Kimi (#3)
Promise: Induced tissue regeneration (iTR), telomerase biology, and cell immortality for aging reversal. Michael West's latest longevity vehicle.
Failure: Failed to advance a clinical longevity product. Chronic financing problems led to stock collapse and delisting. Entered reverse merger with Serina Therapeutics (2024) to avoid bankruptcy. Lead programs failed validation, cash exhausted. The longevity reprogramming hypothesis remained unrealized.
Models: ✓ GPT-5.5 (#9) · ✓ Opus (#10) · ✓ DeepSeek (#13) · ✓ Kimi (#8)
Promise: MultiStem adult stem cells for stroke, trauma, and regenerative aging diseases.
Failure: MASTERS-2 Phase 3 stroke trial failed (2024). Filed for Chapter 11 bankruptcy. Delisted. 30 years of development yielded no approved product. Major clinical programs failed to deliver pivotal success, financing collapsed completely.
Models: ✓ GPT-5.5 (#13) · ✓ Opus (#29) · ✓ DeepSeek (#37) · ✓ Kimi (#12)
Promise: Telomerase activation via small molecules to "cure aging." Bill Andrews' 20+ year quest.
Failure: Never produced a clinically validated drug. Never ran a human trial. Shifted toward supplements and screening. The telomerase activation approach was widely discredited due to cancer risks. Company became effectively dormant — a cautionary tale of a one-idea company without clinical translation.
Models: ✓ GPT-5.5 (#26) · ✓ Opus (#17) · ✓ DeepSeek (#14) · ✓ Kimi (#19)
Promise: Google/Alphabet's moonshot to "solve death." $2.5B+ invested with AbbVie partnership.
Failure: 10+ years and billions spent with zero approved drugs, zero Phase 3 readouts. AbbVie partnership yielded nothing clinically. Quietly abandoned radical longevity messaging. Now a shell of a research lab compared to its original "cure aging" promise. Technically still funded but strategically failed its mission.
Models: ✗ GPT-5.5 · ✓ Opus (#5) · ✓ DeepSeek (#12) · ✓ Kimi (#50)
Promise: NAD+ booster (Basis: NR + pterostilbene) for cellular aging reversal.
Failure: Clinical trials failed to show significant benefit vs placebo for aging biomarkers. Lawsuits with ChromaDex. Class action for false advertising. Reputational collapse. Pivoted to "wellness" — the longevity thesis scientifically failed though company technically still operates in supplement mode.
Models: ✗ GPT-5.5 · ✓ Opus (#9) · ✓ DeepSeek (#8) · ✓ Kimi (#48)
Promise: Young blood plasma transfusions ($8,000/liter) to reverse aging.
Failure: FDA issued safety warning (2019) citing no proven clinical benefit. Forced to halt operations. No efficacy data ever published. No validated rejuvenation product emerged. The most visible "young blood" commercial failure — exploiting parabiosis hype without scientific rigor.
Models: ✓ GPT-5.5 (#25) · ✓ Opus (#13) · ✗ DeepSeek · ✓ Kimi (#6)
Promise: Neural stem cells (HuCNS-SC) for neurodegeneration and age-related brain disease.
Failure: Phase 2 in spinal cord injury failed. Technology unable to demonstrate engraftment or functional improvement. Filed for bankruptcy (2016) and liquidated. Nearly 30 years of stem-cell promise with zero approved products.
Models: ✓ GPT-5.5 (#14) · ✓ Opus (#28) · ✗ DeepSeek · ✓ Kimi (#11)
Promise: Mitochondrial-derived peptides to treat metabolic aging and extend healthspan.
Failure: Lead metabolic-aging candidate CB4211 failed. Pipeline stalled. Cash ran down. Company ceased operations and merged into Morphogenesis/TuHURA. No longevity products ever delivered from the mitochondrial peptide platform.
Models: ✓ GPT-5.5 (#11) · ✓ Opus (#24) · ✓ DeepSeek (#22) · ✗ Kimi
Promise: Mitochondrial-targeted peptides (elamipretide) for mitochondrial and age-related degenerative diseases.
Failure: Elamipretide failed key Phase 3 clinical endpoints in Barth syndrome and primary mitochondrial myopathy. Multiple failures. Delisted from Nasdaq (2022). Taken private at a fraction of value. Anti-aging programs abandoned entirely.
Models: ✓ GPT-5.5 (#23) · ✓ Opus (#19) · ✓ DeepSeek (#23) · ✗ Kimi
Promise: Telomerase and myostatin gene therapy for human rejuvenation. CEO Elizabeth Parrish's self-experimentation.
Failure: Unregulated offshore self-experimentation did not become a regulated therapy. No peer-reviewed data published demonstrating efficacy. No clinical progress. Later analysis showed no measurable telomere effect. Company exists but is effectively a ghost — widely considered a scientific failure.
Models: ✓ GPT-5.5 (#27) · ✗ Opus · ✓ DeepSeek (#7) · ✓ Kimi (#20)
Promise: Adult mesenchymal stem-cell therapies (Prochymal) for inflammatory and degenerative diseases of aging.
Failure: Prochymal failed major indications including Crohn's disease. Did not become a broad regenerative-aging platform. Sold to Mesoblast (2019) for $50M — down from $600M+ peak valuation. Accounting scandal compounded the fall.
Models: ✓ GPT-5.5 (#36) · ✓ Opus (#27) · ✗ DeepSeek · ✓ Kimi (#13)
Promise: Placental expanded (PLX) cells for critical limb ischemia, muscle/vascular aging, and age-related degeneration.
Failure: Phase 3 critical limb ischemia trial failed (2022). COVID programs produced no approvals. Cash runway exhausted. Near-bankruptcy. Company pivoted heavily away from human longevity into food/agtech. Reverse split to avoid delisting.
Models: ✓ GPT-5.5 (#20) · ✓ Opus (#31) · ✗ DeepSeek · ✓ Kimi (#30)
Promise: Calorie-restriction gene-expression profiling to discover anti-aging compounds and CR mimetics.
Failure: Acquired by Nu Skin for $20M. Anti-aging supplements (ageLOC) failed clinical validation for lifespan extension. All longevity R&D discontinued. Shifted into supplement-oriented applications. Never produced an approved calorie-restriction mimetic drug.
Models: ✓ GPT-5.5 (#42) · ✗ Opus · ✓ DeepSeek (#18) · ✓ Kimi (#22)
Promise: Wnt-pathway modulation to regenerate cartilage, hair, skin, and other aging tissues. Valued at $12B at peak.
Failure: Flagship osteoarthritis drug lorecivivint repeatedly missed primary Phase 3 endpoints. No regeneration product reached approval. Valuation collapsed from $12B. Company retreated from its massive anti-aging/regeneration promise and rebranded. A spectacular gap between valuation and delivery.
Models: ✓ GPT-5.5 (#2) · ✓ Opus (#34) · ✗ DeepSeek · ✗ Kimi
| # | Company | Year | Promise | Failure | Score | GPT | Opus | DS | Kimi |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sirtris Pharmaceuticals | 2004 | Sirtuin activators / resveratrol | GSK $720M acquisition → total shutdown | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 2 | Geron Corporation | 1990 | Telomerase / stem cells for aging | Abandoned aging, pivoted to cancer | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 3 | Unity Biotechnology | 2009 | Senolytics for diseases of aging | UBX0101 Phase 2 failure, 95% stock collapse | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 4 | Elixir Pharmaceuticals | 1999 | Sirtuin / ghrelin longevity drugs | $100M+ burned, zero clinical assets | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 5 | resTORbio | 2016 | mTOR inhibition for immunosenescence | Phase 3 failed, merged into Adicet Bio | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 6 | Alkahest | 2014 | Young plasma fractions for brain aging | Grifols terminated after Phase 2 failures | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 7 | AgeX Therapeutics | 2017 | Induced tissue regeneration (iTR) | Delisted, reverse merger to avoid bankruptcy | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 8 | Athersys | 1995 | MultiStem stem cells for stroke/aging | Phase 3 failed, Chapter 11 bankruptcy | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 9 | Sierra Sciences | 1999 | Telomerase activators to cure aging | 20+ years, zero clinical products | 4/4 | ✓ | ✓ | ✓ | ✓ |
| 10 | Calico Life Sciences | 2013 | Google moonshot to "solve death" | $2.5B+, zero approved drugs after 10+ years | 3/4 | ✗ | ✓ | ✓ | ✓ |
| 11 | Elysium Health | 2014 | NAD+ booster (Basis) for aging | Clinical trials failed, class action lawsuits | 3/4 | ✗ | ✓ | ✓ | ✓ |
| 12 | Ambrosia | 2016 | Young blood transfusions | FDA warning, forced to halt, no data | 3/4 | ✓ | ✓ | ✗ | ✓ |
| 13 | StemCells Inc. | 1988 | Neural stem cells for neurodegeneration | Trials failed, bankruptcy, liquidated | 3/4 | ✓ | ✓ | ✗ | ✓ |
| 14 | CohBar | 2007 | Mitochondrial peptides for aging | Lead compound failed, ceased operations | 3/4 | ✓ | ✓ | ✓ | ✗ |
| 15 | Stealth BioTherapeutics | 2006 | Mitochondrial peptides (elamipretide) | Multiple Phase 3 failures, delisted | 3/4 | ✓ | ✓ | ✓ | ✗ |
| 16 | BioViva | 2015 | Gene therapy for rejuvenation | No peer-reviewed data, no clinical progress | 3/4 | ✓ | ✗ | ✓ | ✓ |
| 17 | Osiris Therapeutics | 1992 | MSC stem cells (Prochymal) | Failed indications, sold at massive loss | 3/4 | ✓ | ✓ | ✗ | ✓ |
| 18 | Pluristem / Pluri | 2001 | Placental cells for vascular aging | Phase 3 failed, pivoted to food tech | 3/4 | ✓ | ✓ | ✗ | ✓ |
| 19 | LifeGen Technologies | 2000 | Calorie-restriction mimetics | Sold to Nu Skin, all R&D killed | 3/4 | ✓ | ✗ | ✓ | ✓ |
| 20 | Samumed / Biosplice | 2008 | Wnt pathway regeneration ($12B valuation) | Phase 3 missed endpoints, valuation collapsed | 2/4 | ✓ | ✓ | ✗ | ✗ |
| 21 | Proteostasis Therapeutics | 2006 | Proteostasis network for aging | Pipeline failed, merged into Yumanity | 2/4 | ✓ | ✓ | ✗ | ✗ |
| 22 | TA Sciences / TA-65 | 2002 | Telomerase activator supplement | No proven lifespan effect, FTC scrutiny | 2/4 | ✓ | ✓ | ✗ | ✗ |
| 23 | Navitor Pharmaceuticals | 2012 | Selective mTORC1 modulation | Phase 1b failed, company dissolved | 2/4 | ✗ | ✗ | ✓ | ✓ |
| 24 | Rejuvenate Bio | 2015 | Gene therapy (Yamanaka factors) | Liver toxicity in mice, pivoted away | 2/4 | ✗ | ✓ | ✓ | ✗ |
| 25 | Libella Gene Therapeutics | 2018 | AAV telomerase gene therapy | Pay-to-play offshore trials, effectively defunct | 2/4 | ✓ | ✓ | ✗ | ✗ |
| 26 | Neuralstem / Seneca | 1996 | Neural stem cells for ALS | ALS data failed, merged away from mission | 2/4 | ✓ | ✗ | ✗ | ✓ |
| 27 | BioTime / Lineage Cell | 1990 | Immortalized cell lines for aging | Split up, abandoned anti-aging platform | 2/4 | ✓ | ✗ | ✗ | ✓ |
| 28 | Advanced Cell Technology | 1994 | Embryonic stem cells for aging | Bankrupt 2014, sold to Astellas | 2/4 | ✓ | ✗ | ✗ | ✓ |
| 29 | Cytori Therapeutics | 1996 | Adipose stem cells for cardiac aging | Trials failed, bankrupt 2020 | 2/4 | ✓ | ✗ | ✗ | ✓ |
| 30 | Asterias Biotherapeutics | 2012 | Embryonic stem cells for spinal cord | Failed efficacy, absorbed by Lineage | 2/4 | ✓ | ✗ | ✗ | ✓ |
| 31 | Histogen | 2007 | Cell-secreted growth factors | Hair/skin programs failed, liquidated | 2/4 | ✓ | ✓ | ✗ | ✗ |
| 32 | Frequency Therapeutics | 2014 | Progenitor-cell activation for hearing | FX-322 Phase 2b failed | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 33 | Life Biosciences | 2017 | Sinclair's umbrella for 5+ aging cos | Subsidiaries shut down, restructured | 1/4 | ✗ | ✓ | ✗ | ✗ |
| 34 | Juvenescence | 2017 | Portfolio of longevity drugs | IPO repeatedly withdrawn, stalled | 1/4 | ✗ | ✓ | ✗ | ✗ |
| 35 | Cortexyme / Quince | 2012 | Gingipain inhibitor for aging brain | GAIN trial failed 2021, stock crashed 70% | 1/4 | ✗ | ✓ | ✗ | ✗ |
| 36 | Alteon / Synvista | 1986 | AGE crosslink breakers (alagebrium) | Trials failed, collapsed, delisted | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 37 | Organovo | 2007 | 3D bioprinted tissues/organs | Commercial liver failed, restructured | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 38 | Tengion | 2003 | Lab-grown replacement organs | Out of money, bankruptcy | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 39 | Longeveron | 2014 | MSC for aging frailty | Mixed results, shifted to narrower diseases | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 40 | Biophytis | 2006 | BIO101 for sarcopenia | No approval, financing distress | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 41 | GTX / Oncternal | 1997 | SARMs for sarcopenia | Phase 3 failed, merged away | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 42 | Retrotope | 2006 | Deuterated fatty acids for aging damage | No approved therapy, pipeline stalled | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 43 | Fibrocell Science | 1995 | Autologous fibroblasts for aging skin | Phase 3 failed, bankruptcy 2020 | 1/4 | ✗ | ✗ | ✗ | ✓ |
| 44 | Cambrian Genomics | 2011 | DNA synthesis for radical life extension | CEO suicide, company dissolved | 1/4 | ✗ | ✗ | ✗ | ✓ |
| 45 | Genescient | 2006 | Drosophila genetics for longevity drugs | Faded from existence, zero products | 1/4 | ✗ | ✗ | ✗ | ✓ |
| 46 | BrainStorm Cell Therapeutics | 2000 | NurOwn cells for neurodegeneration | Phase 3 failed, FDA rejected, near-bankrupt | 1/4 | ✗ | ✗ | ✗ | ✓ |
| 47 | Celularity | 2017 | Placental stem cells / cellular medicines | SPAC merged, stock collapsed 95% | 1/4 | ✗ | ✗ | ✗ | ✓ |
| 48 | Evelo Biosciences | 2015 | Microbiome for inflammation/aging | Phase 2 failed, dissolved, delisted | 1/4 | ✗ | ✗ | ✗ | ✓ |
| 49 | Oisin Biotechnologies | 2016 | Senolytic gene therapy | Off-target effects, no human trials, defunct | 1/4 | ✗ | ✗ | ✓ | ✗ |
| 50 | BioAge Labs | 2015 | AI aging drug repurposing | Phase 2 failed, pivoted to obesity | 1/4 | ✗ | ✗ | ✓ | ✗ |
| 51 | Cyclarity Therapeutics | 2013 | Oxidized cholesterol removal | Never entered human trials, dormant | 1/4 | ✗ | ✗ | ✓ | ✗ |
| 52 | Mount Tam Biotechnologies | 2014 | Rapamycin analogs for longevity | Became distressed shell, merged away | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 53 | MyMD Pharmaceuticals | 2014 | Anti-inflammatory for aging/frailty | No approval, merger/restructuring | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 54 | Cardio3 / Celyad | 2007 | C-Cure cell therapy for heart failure | Phase 3 failed, pivoted to CAR-T | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 55 | Replicel Life Sciences | 2010 | Autologous cells for hair/skin aging | Stalled, financing problems, no approval | 1/4 | ✓ | ✗ | ✗ | ✗ |
| 56 | ChromaDex (Tru Niagen) | 1999 | NAD+ booster (nicotinamide riboside) | Trials failed to show lifespan extension | 1/4 | ✗ | ✗ | ✗ | ✓ |
I tried to analyze why these companies fail. One of the most common reasons is the failure to build a credible and sustainable business. There are several examples where companies decided to raise a hell lot of money at the very beginning. These companies are usually very slow, started by physically old management (usually, you need to be old and experienced to raise a lot of money) and in just a few years they start falling apart. VCs that incubate these companies try to cash out early and often start new longevity companies.
Running out of money, clinical failure, or strategic pivot by the investors are among the most common failures.
When I started Insilico I wanted to build a very sustainable business. We could not just focus on aging but had to make aging research into both the source of promising therapeutic targets for age-related diseases and then use these diseases to get deeper insights into biology of aging. There were several times when funding was very tough and we had to do more pharma-only research instead of aging but part of the company was always focused on aging.
Today, we are approaching sustainability and have massive experience incorporating aging research into the drug discovery and development process but it is very important to always look back at history and constantly learn from the mistakes of others. We also can not be comfortable even when the times are very good — only the paranoid survive. In longevity, only the most sustainable and scalable companies will survive.